PRGN-3006
Precigen therapeutics
['leukemia', 'aml,(-streamline),(-seamless),(-kamloops),(-latamleaders)', 'aml,(-streamline),(-seamless),(-kamloops),(-dreamlike)', 'prgn-3006', 'myeloid', '$pgen']
$pgen #asco23 prgn-3006 ultracar-t data from a phase 1 clinical trial in patients with relapsed or refractory acute myeloid leukemia (aml) showed that the therapy was well-tolerated and had promising efficacy. orr was 80%, with 20% of patients achieving cr. 
Anesthesiologist, Pain Management Fellowship, Entrepreneur, Angel Investor.  Aetho, Vireo Labs, C'reer, Enviroflight (now Intrexon/Precigen).